Intoplicine, formerly known as NSC-D-645008; RP-60475, is a DNA topoisomerase I and II inhibitor potentially for the treatment of cancer. Intoplicine interacts with DNA and inhibits both topoisomerases I and II. In vitro it was found cytotoxic against various cell types with greater cytotoxicity towards solid tumor cells. Intoplicine appears to be active in vitro against a variety of human tumors, including a subgroup of tumors insensitive in vitro to standard antineoplastic compounds. References: Denny WA, Baguley BC. Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem. 2003;3(3):339-53. Review. PubMed PMID: 12570767.

纯度：≥98%

CAS：125974-72-3